MedPath

南京赛瑞谱顿制药有限公司

Ownership
-
Established
2021-09-01
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

14

NMPA:14

Drug Approvals

Potassium Chloride Injection

Product Name
氯化钾注射液
Approval Number
国药准字H20253715
Approval Date
Mar 25, 2025
NMPA

Multiple Electrolytes,Sodium Acetate and Glucose Injection

Product Name
复方电解质醋酸钠葡萄糖注射液
Approval Number
国药准字H20253263
Approval Date
Jan 24, 2025
NMPA

Multiple Electrolytes,Sodium Acetate and Glucose Injection

Product Name
复方电解质醋酸钠葡萄糖注射液
Approval Number
国药准字H20253264
Approval Date
Jan 24, 2025
NMPA

Diprophylline Injection

Product Name
二羟丙茶碱注射液
Approval Number
国药准字H20249001
Approval Date
Sep 26, 2024
NMPA

Compound Sodium Acetate and Glucose Injection

Product Name
复方醋酸钠葡萄糖注射液
Approval Number
国药准字H20244291
Approval Date
Jun 28, 2024
NMPA

Compound Sodium Acetate and Glucose Injection

Product Name
复方醋酸钠葡萄糖注射液
Approval Number
国药准字H20244292
Approval Date
Jun 28, 2024
NMPA

Methocarbamol Injection

Product Name
美索巴莫注射液
Approval Number
国药准字H20243970
Approval Date
Jun 11, 2024
NMPA

Ceftazidime for Injection

Product Name
注射用头孢他啶
Approval Number
国药准字H20227120
Approval Date
Sep 21, 2022
NMPA

Ceftazidime for Injection

Product Name
注射用头孢他啶
Approval Number
国药准字H20043405
Approval Date
Jul 22, 2020
NMPA

Ceftazidime for Injection

Product Name
注射用头孢他啶
Approval Number
国药准字H20043406
Approval Date
Jul 22, 2020
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.